Illumina, Inc. (NASDAQ:ILMN) – Equities research analysts at William Blair issued their Q3 2017 earnings per share (EPS) estimates for shares of Illumina in a research note issued to investors on Wednesday. William Blair analyst A. Murphy anticipates that the life sciences company will post earnings per share of $0.99 for the quarter. William Blair also issued estimates for Illumina’s Q4 2017 earnings at $1.16 EPS, Q1 2018 earnings at $1.01 EPS, Q2 2018 earnings at $1.03 EPS, Q3 2018 earnings at $1.17 EPS and Q4 2018 earnings at $1.14 EPS.
Other equities analysts also recently issued reports about the stock. Vetr downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 target price for the company. in a report on Wednesday, May 31st. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $195.00 target price for the company in a report on Thursday, July 27th. Canaccord Genuity upgraded shares of Illumina from a “hold” rating to a “buy” rating and boosted their target price for the stock from $170.00 to $215.00 in a report on Monday, August 7th. First Analysis upgraded shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 target price for the company in a report on Wednesday, August 2nd. Finally, Barclays PLC reiterated an “equal weight” rating and issued a $150.00 target price on shares of Illumina in a report on Wednesday, August 9th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $177.01.
COPYRIGHT VIOLATION WARNING: “William Blair Comments on Illumina, Inc.’s Q3 2017 Earnings (ILMN)” was first posted by BBNS and is the property of of BBNS. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://baseballnewssource.com/markets/william-blair-comments-on-illumina-inc-s-q3-2017-earnings-ilmn/1565699.html.
Shares of Illumina (ILMN) opened at 204.46 on Friday. Illumina has a 12 month low of $119.37 and a 12 month high of $205.21. The company’s 50-day moving average is $186.97 and its 200 day moving average is $177.03. The stock has a market capitalization of $29.85 billion, a P/E ratio of 41.02 and a beta of 0.83.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The company had revenue of $662 million for the quarter, compared to the consensus estimate of $642.38 million. During the same period in the prior year, the firm posted $0.86 EPS. Illumina’s revenue for the quarter was up 10.3% on a year-over-year basis.
Hedge funds and other institutional investors have recently made changes to their positions in the company. First Citizens Bank & Trust Co. increased its position in Illumina by 0.4% in the second quarter. First Citizens Bank & Trust Co. now owns 3,088 shares of the life sciences company’s stock valued at $536,000 after buying an additional 12 shares in the last quarter. Patten Group Inc. increased its position in Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after buying an additional 25 shares in the last quarter. Puzo Michael J increased its position in Illumina by 0.4% in the second quarter. Puzo Michael J now owns 5,955 shares of the life sciences company’s stock valued at $1,032,000 after buying an additional 25 shares in the last quarter. Flagship Harbor Advisors LLC increased its position in Illumina by 1.7% in the second quarter. Flagship Harbor Advisors LLC now owns 2,046 shares of the life sciences company’s stock valued at $345,000 after buying an additional 35 shares in the last quarter. Finally, Eqis Capital Management Inc. increased its position in Illumina by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 6,914 shares of the life sciences company’s stock valued at $1,200,000 after buying an additional 38 shares in the last quarter. 93.32% of the stock is owned by institutional investors and hedge funds.
In other news, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $184.75, for a total transaction of $26,788.75. Following the completion of the transaction, the senior vice president now directly owns 10,791 shares of the company’s stock, valued at approximately $1,993,637.25. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Jay T. Flatley sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 18th. The stock was sold at an average price of $170.77, for a total value of $2,561,550.00. Following the transaction, the director now directly owns 534,176 shares of the company’s stock, valued at $91,221,235.52. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 159,945 shares of company stock valued at $29,365,458. Corporate insiders own 1.60% of the company’s stock.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with our FREE daily email newsletter.